Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Stock Up 3.9 %

Minerva Neurosciences stock opened at $1.61 on Thursday. The stock’s 50 day moving average is $1.89 and its 200 day moving average is $2.21. The company has a market capitalization of $11.26 million, a P/E ratio of -3.66 and a beta of 0.10. Minerva Neurosciences has a twelve month low of $1.42 and a twelve month high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.49. As a group, equities analysts expect that Minerva Neurosciences will post -0.3 EPS for the current year.

Hedge Funds Weigh In On Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Northern Trust Corp increased its stake in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 60.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,878 shares of the biopharmaceutical company’s stock after purchasing an additional 13,829 shares during the quarter. Northern Trust Corp owned 0.53% of Minerva Neurosciences worth $82,000 at the end of the most recent quarter. Institutional investors own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.